Table 2 Significantly enriched metabolic pathways following EP treatment in the CCI injured brain
From: Metabolic-driven analytics of traumatic brain injury and neuroprotection by ethyl pyruvate
Enriched Pathways | Holm | FDR | Impact | Metabolite hits |
|---|---|---|---|---|
Pyruvate metabolism | 5.6E−03 | 1.3E−03 | 0.154 | Acetyl-CoA; phosphoenolpyruvate |
Citrate cycle (TCA cycle) | 5.6E−03 | 1.3E−03 | 0.037 | Acetyl-CoA; phosphoenolpyruvate |
Fatty acid elongation | 1.7E−02 | 1.3E−03 | 0.037 | Acetyl-CoA |
Fatty acid degradation | 1.7E−02 | 1.3E−03 | 0.181 | Acetyl-CoA |
Beta-alanine metabolism | 1.7E−02 | 1.3E−03 | 0.056 | Acetyl-CoA |
Valine, leucine and isoleucine degradation | 1.7E−02 | 1.3E−03 | 0.028 | Acetyl-CoA |
Propanoate metabolism | 1.7E−02 | 1.3E−03 | 0.013 | Acetyl-CoA |
Fatty acid biosynthesis | 1.7E−02 | 1.3E−03 | 0.002 | Acetyl-CoA |
Glycolysis/gluconeogenesis | 1.7E−02 | 2.0E−03 | 0.246 | Acetyl-CoA; 2-Phospho-d-glycerate; Phosphoenolpyruvate |
Purine metabolism | 1.8E−02 | 2.3E−03 | 0.060 | Adenosine 5ʹ-monophosphate; adenosine |
Glyoxylate and dicarboxylate metabolism | 1.8E−02 | 2.3E−03 | 0.008 | Acetyl-CoA; 2-Phospho-d-glycerate |
Cysteine and methionine metabolism | 1.8E−02 | 2.5E−03 | 0.096 | l-Cystine; l-Cysteine |
Glycine, serine and threonine metabolism | 2.6E−02 | 3.9E−03 | 0.002 | 2-Phospho-d-glycerate; l-Cysteine |
Glutathione metabolism | 5.1E−02 | 9.4E−03 | 0.260 | 2-Phospho-d-glycerate; l-Cysteine |
Nicotinate and nicotinamide metabolism | 5.4E−02 | 1.1E−02 | 0.032 | Nicotinamide d-ribonucleotide |